Holen Sie sich die Stockscreener-App
8.61
0.46%
-0.04
Handel nachbörslich:
8.62
0.010
+0.12%
Biocryst Pharmaceuticals Inc Aktie (BCRX) Neueste Nachrichten
What drives BioCryst Pharmaceuticals Inc. stock priceConsistent high-performance stocks - Autocar Professional
BioCryst Pharmaceuticals Enters Oversold Territory (BCRX) - Nasdaq
BioCryst Pharmaceuticals Inc. Stock Analysis and ForecastFree Consultation - Autocar Professional
BioCryst to Report Second Quarter 2025 Financial Results on August 4 - GlobeNewswire
Is BioCryst Pharmaceuticals Inc. a good long term investmentFree High-Return Strategy Alerts - jammulinksnews.com
What analysts say about BioCryst Pharmaceuticals Inc. stockFree Stock Selection - Autocar Professional
BioCryst: ORLADEYO Powers Profitability Amidst Rising HAE Competition (NASDAQ:BCRX) - Seeking Alpha
BioCryst Pharmaceuticals to Announce Q2 2025 Financial Results and Host Conference Call on August 4, 2025 - Quiver Quantitative
How To Trade (BCRX) - news.stocktradersdaily.com
BioCryst appoints Babar Ghias as CFO - MSN
Will BioCryst Pharmaceuticals Inc. stock benefit from AI tech trendsCarefully Curated High Return Stocks - beatles.ru
BioCryst Pharmaceuticals (BCRX) Rallies 1.28% Amid Analyst Coverage - AInvest
AscellaHealth’s Patient-Focused Approach is Best-in-Class Model for Distribution of Rare Disease Therapies - GlobeNewswire Inc.
Zacks.com featured highlights ASR, INSW, BCRX, ASC and RRGB - The Globe and Mail
RBC Capital Maintained a Buy on BioCryst Pharmaceutical (BCRX), Sets a PT of $13 - MSN
BioCryst to Highlight Patient-focused Research at the 2025 US HAEA National Summit - GlobeNewswire
BioCryst Unveils Groundbreaking Research on HAE Treatment Burden in Young Patients Under 12 - Stock Titan
Island Pharmaceuticals announces purchase of Galidesivir antiviral program from Biocryst Pharmaceuticals - MarketScreener
Island Pharmaceuticals acquires BioCryst’s Galidesivir - grafa.com
BioCryst Pharmaceuticals appoints Babar Ghias as CFO By Investing.com - Investing.com South Africa
BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development - GlobeNewswire
Island Pharmaceuticals Acquires Galidesivir Antiviral Program from BioCryst Pharmaceuticals - AInvest
CFO changes at Biocryst, Xenon, Century, Pyxis - biocentury.com
Missed PDUFA history as Kalvista wins FDA approval for HAE - BioWorld MedTech
Is BioCryst Pharmaceuticals (BCRX) Outperforming Other Medical Stocks This Year? - Yahoo
BioCryst Pharmaceuticals (BCRX) Appoints New CFO, Babar Ghias - GuruFocus
BioCryst Pharmaceuticals Appoints Babar Ghias as Chief Financial Officer and Head of Corporate Development - Quiver Quantitative
BioCryst Pharmaceuticals appoints Babar Ghias as CFO - Investing.com
BioCryst Taps Dealmaking Powerhouse as New CFO: $80B Transaction Expert to Drive Growth Strategy - Stock Titan
BioCryst Pharmaceuticals shares rise 1.37% after-hours following the appointment of Babar Ghias as CFO. - AInvest
BioCryst Appoints Babar Ghias Chief Financial Officer and Head o - GuruFocus
BioCryst Pharmaceuticals Sells European ORLADEYO Business for Up to $264M - Insider Monkey
10 Best High Short Interest Stocks With Huge Upside Potential - Insider Monkey
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
BioCryst Expands Team with 57,000 Share RSU Package: Latest Details on New Hiring Spree - Stock Titan
BioCryst Pharma (BCRX) Receives Boost with Increased Price Target | BCRX Stock News - GuruFocus
1.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):